Blinatumomab (10) – Blincyto®

Acute lymphocytic B-cell leukaemia, CD19+, relapsed or refractory, adults

Characteristics

Start date 01.06.2026 – Marketing authorisation: 23.11.2015
Resolution 19.11.2026
INN Blinatumomab
Brand name Blincyto®
Pharm. company Amgen GmbH
G-BA Procedure ID D-1324
Therapeutic area Oncological diseases Orphan (turnover limit)
Reason for procedure Reassessment: Orphan turnover exceeded

Studies and Results

  • Clinical trials
    • For benefit assessment, the pharmaceutical manufacturer has submitted the results of the TOWER trial. This was an open-label, randomised, multicentre Phase III trial in which blinatumomab was compared with four chemotherapy regimens.

a) Adults with Philadelphia chromosome-positive, CD19-positive, relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), in whom treatment with at least two tyrosine kinase inhibitors (TKIs) has failed and who have no alternative treatment options

  • The pharmaceutical manufacturer has not submitted any study comparing blinatumomab with the appropriate comparator therapy.
  • No data comparing the drug with the appropriate comparator therapy have been submitted. Consequently, no additional benefit has been demonstrated for blinatumomab in the treatment of adults with Philadelphia chromosome-positive, CD19-positive, relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), in whom treatment with at least two tyrosine kinase inhibitors (TKIs) has failed and who have no alternative treatment options, proof that the appropriate comparator therapy is better than the current standard of care is not proven.

b1) Adults with Philadelphia chromosome-negative, CD19-positive, relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), for whom chemotherapy is not the appropriate treatment option

  • The comparator therapy in the present TOWER study did not include immunotherapy with inotuzumab ozogamicin. No data are available on the additional benefit for patients for whom chemotherapy is not the appropriate treatment on an individual basis. There is therefore no additional benefit for blinatumomab in the treatment of adults with Philadelphia chromosome-negative, CD19-positive, relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), for whom chemotherapy is not the appropriate treatment option, with no proof that it is better than the appropriate comparator therapy.

b2) Adults with Philadelphia chromosome-negative, CD19-positive, relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), for whom chemotherapy is the appropriate treatment option

  • Overall, evaluable data are available for overall survival alone. Consequently, for the treatment of patients with Philadelphia chromosome-negative, CD19-positive, relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), for whom chemotherapy is the appropriate treatment option, blinatumomab is found to provide an additional benefit over chemotherapy, the extent of which is non-quantifiable.
  • With regard to the certainty of the findings, a hint of the identified additional benefit is derived.
  • No assessable data are available for the endpoint categories of morbidity, quality of life and side effects.
  • mortality
    • For overall survival, the primary data analysis shows a significant advantage in favour of blinatumomab, with a median benefit of 3.7 months (7.7 months in the blinatumomab arm compared with 4.0 months in the chemotherapy arm).
    • For the endpoint of overall survival, there is a statistically significant difference in favour of blinatumomab compared with chemotherapy. The results for overall survival are subject to uncertainties which do not call the advantage into question but do affect the assessment of the extent of the advantage.
  • morbidity
    • The results for the patient-reported endpoints are therefore not suitable for benefit assessment.
  • quality of life
    • As the response rates are comparable to those for the symptom scales of the EORTC QLQ-C30, the results for health-related quality of life are, in line with the comments in the ‘Symptoms’ section, not considered usable overall.
  • Side effects
    • For the purposes of this assessment, the data are therefore presented for supplementary purposes only.
  • Overall assessment
    • In the overall assessment of the available results for patient-relevant endpoints, evaluable data are available for overall survival alone. The assessment of the extent of the advantage in overall survival is subject to uncertainties. Consequently, for the treatment of patients with Philadelphia chromosome-negative, CD19-positive, relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), for whom chemotherapy is the appropriate treatment option, blinatumomab is found to offer additional benefit over chemotherapy, the extent of which is non-quantifiable.

Courtesy translation only, please refer to the German original.

Associated procedures

Blinatumomab (14) Blincyto® Amgen GmbH Oncological diseases Acute lymphocytic B-cell leukaemia, Ph-, CD19+, newly diagnosed, adults 160–280 100% Hint for considerable additional benefit Orphan (turnover limit)
Blinatumomab (13) Blincyto® Amgen GmbH Oncological diseases Acute lymphocytic B-cell leukaemia, Ph-, CD19+, high-risk first relapse, children aged ≥1 month 10–40 100% Indication of major additional benefit Orphan (turnover limit)
Blinatumomab (12) Blincyto® Amgen GmbH Oncological diseases Acute lymphocytic B-cell leukaemia, Ph-, CD19+, MRD-positive, adults 10–40 100% additional benefit not proven Orphan (turnover limit)
Blinatumomab (11) Blincyto® Amgen GmbH Oncological diseases Acute lymphocytic B-cell leukaemia, Ph-, CD19+, relapsed/refractory, following ≥ 2 prior treatments or following allogeneic haematopoietic stem cell transplantation, children aged ≥ 1 month 40–90 100% additional benefit not proven Orphan (turnover limit)
Blinatumomab (10) Blincyto® Amgen GmbH Oncological diseases Acute lymphocytic B-cell leukaemia, CD19+, relapsed or refractory, adults 49–170 46% Hint for non-quantifiable additional benefit Orphan (turnover limit)
Blinatumomab (8) Blincyto® Amgen GmbH Oncological diseases Acute lymphoblastic B-cell leukaemia, high-risk first relapse, Ph-, CD19+, ≥1 month and <1 year 1
1
100% Hint for non-quantifiable additional benefit Orphan repealed
Blinatumomab (9) Blincyto® Amgen GmbH Oncological diseases Acute lymphoblastic B-cell leukaemia, Ph-, CD19+, newly diagnosed 160–270
160–270
100% Hint for considerable additional benefit Orphan repealed
Blinatumomab (7) Blincyto® Amgen GmbH Oncological diseases Acute lymphoblastic B-cell leukaemia, relapsed/refractory, ≥ 1 month to < 1 year, after ≥ 2 prior therapies or after allogeneic stem cell transplantation 1
1
100% Hint for non-quantifiable additional benefit Orphan repealed
Blinatumomab (6) Blincyto® Amgen GmbH Oncological diseases B-cell acute lymphoblastic leukaemia (ALL), high-risk first relapse, Ph-, CD19+, 1 to ≤ 18 years 7–30
7–30
100% Indication of major additional benefit Orphan repealed
Blinatumomab (5) Blincyto® Amgen GmbH Oncological diseases B-cell acute lymphoblastic leukaemia, relapsed or refractory, Ph+ CD19+ 5–10
5–10
100% Hint for non-quantifiable additional benefit Orphan repealed
Blinatumomab (4) Blincyto® Amgen GmbH Oncological diseases B-cell acute lymphoblastic leukaemia (ALL), MRD-positive patients 40–110
40–110
100% non-quantifiable additional benefit Orphan repealed
Blinatumomab (3) Blincyto® Amgen GmbH Oncological diseases B-cell acute lymphoblastic leukaemia (ALL), ≥ 1 to <18 years 30–80
30–80
100% non-quantifiable additional benefit Orphan repealed
Blinatumomab (2) Blincyto® Amgen GmbH Oncological diseases B-cell acute lymphoblastic leukaemia (ALL) 60–170
60–170
100% considerable additional benefit Orphan repealed
Blinatumomab (1) Blincyto® Amgen GmbH Oncological diseases B-cell acute lymphoblastic leukaemia (ALL) 0
60–170
100% non-quantifiable additional benefit Orphan repealed


<< List of all resolutions